Improved performance of a double antibody radioimmunoassay for carcinoembryonic antigen.
A new double antibody solid-phase radioimmunoassay (RIA) for carcinoembryonic antigen (CEA) is critically analyzed. The aim of the study was 4-fold: (a) to define the level of sensitivity (a comparison of 3 different assay procedures revealed that our sequential assay was more sensitive than most previously reported RIAs, while competitive and non-equilibrium assay had wider measuring ranges); (b) to analyze recoveries of CEA in either serum, plasma or urine (the recovery, even in urine, was very close to expected values, indicating that no CEA is lost or degraded during brief storage or in the extraction procedure); (c) to evaluate inter- and intra-assay variations, since most clinical management is dependent on serial assays rather than single determinations. The coefficients of variation were low both within and between assays. A change of 3 ng CEA is required for significant change (greater than 2 S.D.) at the normal serum level which is 16 ng CEA/ml in our assay. At levels above normal, a change of 4 ng is required; (d) the assay was also developed for determination of CEA levels in a large series of perchlorid acid treated serum, plasma or urine samples. This forms the basis for an assay suitable for serial assays with high sensitivity and accuracy in various neoplastic diseases.
D000818:Animals; D000918:Antibody Specificity; D002272:Carcinoembryonic Antigen / Q000276:immunology* / Q000652:urine; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D007106:Immune Sera / Q000494:pharmacology; D010472:Perchlorates / Q000494:pharmacology; D011817:Rabbits; D011863:Radioimmunoassay
D002272:Carcinoembryonic Antigen; D007106:Immune Sera; D010472:Perchlorates